Elevated Plasma Aldosterone Levels Despite Complete Inhibition of the Vascular Angiotensin-Converting Enzyme in Chronic Heart Failure

Circulation. 2002;106:1055-1057; originally published online August 5, 2002; doi: 10.1161/01.CIR.0000030935.89559.04
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/106/9/1055
Elevated Plasma Aldosterone Levels Despite Complete Inhibition of the Vascular Angiotensin-Converting Enzyme in Chronic Heart Failure

Ulrich P. Jorde, MD; Timothy Vittorio, MD; Stuart D. Katz, MD; Paolo C. Colombo, MD; Farhana Latif, MD; Thierry H. Le Jemtel, MD

Background—Plasma aldosterone levels are elevated in patients with chronic heart failure (CHF) taking angiotensin-converting enzyme (ACE) inhibitors. Elevated aldosterone levels may reflect incomplete inhibition of the vascular converting enzyme during long-term ACE inhibition. We simultaneously measured plasma aldosterone levels and the degree of inhibition of the vascular converting enzyme in patients with CHF.

Methods and Results—Thirty-four subjects with CHF receiving the maximum recommended doses of ACE inhibitors for a duration of 3 to 105 months were studied. The pressor response to exogenous angiotensin I (AI) was measured and normalized for the pressor response to angiotensin II (AII) to assess inhibition of the vascular converting enzyme (AII/AI ratio). Aldosterone levels were determined by solid-phase radioimmunoassay. Eleven of the 34 subjects had plasma aldosterone levels above the upper limit of normal, ie, >15.0 ng/dL. Seven of these 11 subjects (64%) had an AII/AI ratio ≤0.05, indicating complete inhibition of the vascular converting enzyme. In the entire cohort, the AII/AI ratio did not correlate with the duration of ACE inhibitor therapy.

Conclusions—Plasma aldosterone levels are elevated in patients with CHF during long-term ACE inhibitor therapy despite complete inhibition of the vascular converting enzyme. Complete inhibition of the vascular converting enzyme does not obviate the need for aldosterone receptor blockade in patients with CHF. (Circulation. 2002;106:1055-1057.)

Key Words: heart failure • angiotensin • aldosterone

Plasma aldosterone levels are elevated in patients with chronic heart failure (CHF) receiving standard doses of angiotensin-converting enzyme (ACE) inhibitors, and adding aldosterone receptor blockade to the treatment reduces mortality in these patients.1,2 We have previously demonstrated that a substantial proportion of patients with CHF receiving the maximum recommended doses of ACE inhibitors are still able to generate angiotensin II (AII) after exogenous administration of angiotensin I (AI), which indicated an incomplete inhibition of the vascular converting enzyme.3 In the present study, we hypothesized that plasma aldosterone levels are elevated during long-term ACE inhibitor therapy in patients with incomplete inhibition of the vascular converting enzyme but are normal in patients with complete inhibition. We measured plasma aldosterone level and the degree of inhibition of the vascular converting enzyme in 34 subjects with CHF who had been receiving ACE inhibitors for at least 3 months.

Methods

Study Population
We studied 34 clinically stable subjects with CHF and a left ventricular ejection fraction ≤40% who were in a steady-state fluid balance as evidenced by stable, nonedematous body weight, stable electrolytes, and renal function. All subjects were on a 2-g sodium diet and were receiving the maximum recommended doses of long-acting ACE inhibitors (40 mg daily for enalapril, fosinopril, and lisinopril; 4 mg for trandolapril) for at least 3 months.4,5 Exclusion criteria were serum potassium ≤3.7 or ≥5.3 mmol/L, serum creatinine ≥2.0 mg/dL, serum sodium ≥142 mmol/L per liter, and prior or current treatment with spironolactone. All subjects signed informed consent approved by the local Institutional Review Board.

Assessment of Vascular ACE Inhibition
The pressor response to AI and AII was measured noninvasively with arterial tonometry (Colin Pilot Monitor 9200). Peak increase in radial artery systolic pressure (RASP) occurs 60 to 100 seconds after administration of exogenous AI and AII (Clinalfa Ag). The greatest increase in RASP from baseline after administration of AI and AII was selected from continuous tracings by an investigator (S.D.K.) blinded to study design.

Graded doses of exogenous AI (10 to 200 ng/kg) were administered intravenously to increase RASP by 20 mm Hg. After return to baseline RASP, graded doses of AII (2 to 40 ng/kg) were administered to increase RASP by 20 mm Hg. The pressor response to AII was linear up to 20 mg Hg in every subject. Thus, the amount of AI generated after administration of AII could be inferred from the change in RASP, and the ratio of AII/AI was calculated. An AII/AI ratio of <0.05 indicates complete inhibition of the vascular convert-
ing enzyme.6 Pressor response to AI and AII was measured 3 hours after administration of ACE inhibitor.7

Plasma Aldosterone Levels
Ten milliliters of venous blood was drawn from subjects resting supine for 20 minutes after insertion of an 20-gauge angiocath into a superficial vein of the opposite forearm between 10 and 12 AM and before administration of AI and AII. Samples were frozen immediately at −70°C. Solid-phase radioimmunoassay was used for determination of plasma aldosterone (Diagnostics Product Cooperation). The intra- and interassay coefficients were <10%.

Statistical Analysis
Associations between continuous variables were determined with univariate linear regression analysis (SPSS 10.1 software). Associations between categorical variables were determined with χ² analysis. A 2-tailed probability value <0.05 was used to infer statistical significance.

Results
Clinical characteristics, laboratory values, and background medications are summarized in the Table.

The AII/AI ratio ranged from 0.01 to 0.33 (median 0.037; mean 0.067). Twenty-three of the 34 subjects had an AII/AI ratio <0.05, which indicated complete inhibition of the vascular converting enzyme. The AII/AI ratio was unrelated to the duration of ACE inhibitor therapy, which ranged from 3 to 105 months (Figure 1).

Plasma aldosterone levels ranged from 2.5 to 42.1 ng/dL (median 9.7; mean 13.4 ng/dL). Twenty-three of the 34 subjects had a normal plasma aldosterone level, ie, ≤15.0 ng/dL. The remaining 11 subjects had elevated plasma aldosterone levels. Seven of these 11 subjects (64%) had an AII/AI ratio ≤0.05, which indicated complete inhibition of the vascular converting enzyme. Plasma aldosterone level and AII/AI ratio did not correlate (Figure 2) and were unrelated to the type of ACE inhibitor used. Plasma aldosterone levels were unrelated to serum potassium and sodium concentrations or diuretic doses.

Discussion
The present data clearly indicate that plasma aldosterone levels are elevated in patients with CHF, even when treatment with ACE inhibitors results in complete inhibition of the vascular converting enzyme. The data also suggest that the degree of inhibition of the vascular converting enzyme is independent of the duration of ACE inhibitor therapy.

Determination of residual ACE activity, direct measurement of circulating AI and AII, and the pressor response to AI are the methods used to estimate the degree of inhibition of the converting enzyme during ACE inhibitor therapy. Determination of ACE activity varies with substrate and assay conditions and thus may not always accurately reflect the
degree of converting enzyme inhibition. Measurement of circulating AII is technically challenging, and its relevance in assessing the degree of inhibition of the converting enzyme has been questioned. In contrast, the pressor response to AI, when normalized by the pressor response to AII, provides a reproducible functional bioassay to quantify the activity of the circulating and endothelium-bound converting enzyme.

Inhibition of the vascular converting enzyme as assessed by the pressor response to AI was complete in 7 of 11 (64%) patients with elevated plasma aldosterone levels. Continuous aldosterone formation in patients with complete inhibition of the vascular converting enzyme may be attributable to AII generation via non-ACE pathways or AII-independent stimuli of aldosterone production, such as intravascular depletion, potassium, corticotropin, endothelin, and catecholamines. Within the narrow range of potassium concentrations allowed in patients who were per protocol in a euvolemic state, plasma aldosterone levels did not correlate with serum potassium concentrations. Although we did not measure catecholamine levels, it is of note that aldosterone levels were elevated in 9 of 29 (31%) of the patients receiving both β-blockers and ACE inhibitors.

Our findings are concordant with previously reported observations in patients with hypertension, in whom the plasma AII/AI ratio and plasma aldosterone do not correlate, and in patients with CHF, in whom plasma aldosterone levels do not seem to correlate with the activity of the renin-angiotensin system.

Incomplete inhibition of the vascular converting enzyme was not related to the duration of ACE inhibitor therapy. This finding, albeit collected in a cross-sectional study, contrasts with results reported by other investigators who noted an increase in AI/AII conversion over time. The disparity between previous reports and ours cannot be readily explained. Although differences in methodology may be in part responsible for the divergent results, our findings suggest that factors other than time might contribute to ACE escape, which thus seems to be a more complex phenomenon than initially thought.

In summary, plasma aldosterone levels are elevated in patients with CHF, even when long-term ACE inhibitor therapy results in complete inhibition of the vascular converting enzyme. AII-independent stimuli of aldosterone production may account for this finding, and complete ACE inhibition does not obviate the need for aldosterone receptor blockade in patients with CHF.

Acknowledgments
This work was supported by grants from the National Heart, Lung, and Blood Institute (K23-HL04381 to Dr Jorde; K24-HL04024 to Dr Katz) and the American Heart Association (GIA 9951050T to Dr Le Jemtel).

References